BIGBEAR
PHARMACEUTICAL
Tazemetostat is the world’s first orally administered, selective EZH2 (enhancer of zeste homolog 2) inhibitor approved for marketing, and it belongs to epigenetic targeted therapeutic agents.
AuthenticGuaranteeFast DeliveryPrivacy Role of EZH2 in TumorigenesisEZH2 is a protein present in many human cells that helps regulate B‑cell development.Mutations in EZH2 cause hyperactivit···【More】
Update: 10 Mar,2026Source: BigbearViews: 111
FDA Approval AnnouncementEpizyme, a biopharmaceutical company dedicated to developing novel epigenetic therapies, recently announced that the U.S. Foo···【More】
Update: 10 Mar,2026Source: BigbearViews: 113
Japan Approval AnnouncementEisai recently announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Tazverik (tazemetosta···【More】
Update: 10 Mar,2026Source: BigbearViews: 114
Approval AnnouncementEisai recently announced that Japan has approved the anticancer drug Tazverik (tazemetostat, 200 mg tablets) for the treatment of···【More】
Update: 10 Mar,2026Source: BigbearViews: 113
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
